AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the
“Company”), a national provider of premium body contouring
procedures, today announced results for the fourth quarter and full
year ended December 31, 2021.
Fourth Quarter
- Cases increased 43.8% from prior year period to 2,885
cases
- Revenue increased 64.4% from prior year period to $37.6 million
- Same-center revenue per case increased 13.1% from the prior
year period
- Same-center cases increased 19.6% from the prior year
period
- Net loss was $14.2 million as compared to the prior year period
net income of $5.6 million
- Adjusted EBITDA increased to $10.2 million, growth of 25.8%
over the prior year period
Full Year
- Cases increased 87.8% from prior year period to 11,050
cases
- Revenue increased 112.4% from prior year period to $133.3
million
- Same-center revenue per case increased 12.1% from the prior
year period
- Same-center cases increased 55.5% from the prior year
period
- Net income was $10.6 million as compared to the prior year
period of $7.6 million
- Adjusted EBITDA increased to $46.1 million, growth of 163.5%
over the prior year period
“We are very pleased with our financial performance for the
quarter and for the full year 2021. We produced exceptional growth
and are excited about the momentum we have moving into 2022,” said
Dr. Aaron Rollins, Chief Executive Officer of AirSculpt
Technologies. “Our performance for 2021 highlights the demand for
our first class body contouring services as evidenced by our case
and revenue per case growth rates. We continue to see
strong demand for our services and since our IPO in October, we
have opened new centers in Miami Beach, Salt Lake City and our
newest center opened this week in Las Vegas.”
“While the quarter provided some challenges due to the omicron
variant, we were able to exceed our revenue guidance which is
significant, given the patient scheduling and staffing related
challenges we had to address due to Covid related obstacles. The
opening of two centers in the fourth quarter and our announcement
today of our Las Vegas center opening continues to demonstrate our
ability to execute on our de novo strategy,” said Ron Zelhof, Chief
Operating Officer. “Our pipeline of de novo opportunities continues
to be strong, and we look forward to delivering exceptional
services to these new communities and others as we expand across
the country.”
Fourth Quarter 2021 Results
Case volume was 2,885 for the fourth quarter of 2021,
representing growth of 43.8% over the prior year period case volume
of 2,006. Revenue for the fourth quarter of 2021 increased by 64.4%
to $37.6 million from $22.8 million in the prior year period.
Same-center cases and revenue per case for the fourth quarter of
2021 were up 19.6% and 13.1%, respectively, over the prior year
period. Net loss for the quarter was $14.2 million compared to net
income of $5.6 million in the prior year period. For the fourth
quarter 2021, the Company’s adjusted EBITDA grew 25.8% to $10.2
million as compared to $8.1 million for the prior year period.
Full Year 2021 Results
Case volume was 11,050 for the full year 2021, representing
growth of 87.8% over the prior year period case volume of 5,885.
Revenue for 2021 increased by 112.4% to $133.3 million from $62.8
million in the prior year period. Same-center cases and revenue per
case for 2021 were up 55.5% and 12.1%, respectively, over the prior
year period. Full year net income for 2021 grew to $10.6 million
compared to $7.6 million from the prior year period. For full year
2021, the Company’s adjusted EBITDA grew 163.5% to $46.1 million as
compared to $17.5 million for the prior year period.
2022 Outlook
The Company projects full year revenue and Adjusted EBITDA 2022
guidance as follows:
- Revenues in the range of $172 million to $176 million
representing growth of 29% to 32% over 2021
- Adjusted EBITDA in
the range of $58 million to $60 million representing growth of 26%
to 30% over 2021
- The addition of four
new centers, one opening in the first quarter and three in the
second half of the year
The guidance above assumes there will be no material negative
impact in market conditions from any new COVID strains.
Liquidity
As of December 31, 2021, the Company had $25.3 million in cash
and cash equivalents and $5.0 million of borrowing capacity under
its revolving credit facility.
The Company had $26.6 million and $14.0 million in operating
cash flows for the full year 2021 and 2020, respectively. The
increase is primarily driven by improved income from operations
related to opening four new centers in the 12 months ended December
31, 2021 and an increase in same center volumes and revenue which
were impacted by the COVID-19 pandemic in the second and third
quarters of 2020.
Conference Call Information
AirSculpt will hold a conference call today, March 11, 2022 at
8:30 am (Eastern Time). The conference call can be accessed live
over the phone by dialing 1-877-407-9716 or for international
callers, 1-201-493-6779. A replay will be available two hours after
the call and can be accessed by dialing 1-844-512-2921, or for
international callers, 1-412-317-6671. The passcode for the live
call and the replay is 13726492. The replay will be available until
March 18, 2022.
Interested investors and other parties may also listen to a
simultaneous webcast of the conference call by logging onto the
Investor Relations section of the Company’s website at
https://investors.elitebodysculpture.com/. The online replay will
be available for one week following the call.
About AirSculpt Technologies
AirSculpt Technologies is an experienced, fast-growing national
provider of body contouring procedures delivering a premium
consumer experience under its brand, Elite Body Sculpture. At Elite
Body Sculpture, we provide custom body contouring using our
proprietary AirSculpt® method that removes unwanted fat in a
minimally invasive procedure, producing dramatic results. It is our
mission to generate the best results for our patients.
Forward-Looking Statements
This press release contains forward-looking statements. In some
cases, you can identify these statements by forward-looking words
such as “may,” “might,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential” or
“continue,” the negative of these terms and other comparable
terminology. These forward-looking statements, which are subject to
risks, uncertainties, and assumptions about us, may include
projections of our future financial performance, our anticipated
growth strategies, and anticipated trends in our business. These
statements are only predictions based on our current expectations
and projections about future events. There are important factors
that could cause our actual results, level of activity,
performance, or achievements to differ materially from the results,
level of activity, performance or achievements expressed or implied
by the forward-looking statements, including those factors
discussed in the section titled “Risk Factors” in our Annual Report
on Form 10-K.
Our future results could be affected by a variety of other
factors, including, but not limited to, failure to open and operate
new centers in a timely and cost-effective manner; shortages or
quality control issues with third-party manufacturers or suppliers;
competition for surgeons; litigation or medical malpractice claims;
inability to protect the confidentiality of our proprietary
information; changes in the laws governing the corporate practice
of medicine or fee-splitting; changes in the regulatory, economic
and other conditions of the states and jurisdictions where our
facilities are located; and business disruption or other losses
from war, pandemic, terrorist acts or political unrest.
The risk factors discussed in “Risk Factors” in our Annual
Report on Form 10-K could cause our results to differ materially
from those expressed in the forward-looking statements made in this
press release.
There also may be other risks that are currently unknown to us
or that we are unable to predict at this time.
Although we believe the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, level of activity, performance, or achievements.
Moreover, neither we nor any other person assumes responsibility
for the accuracy and completeness of any of these forward-looking
statements. Forward-looking statements speak only as of the date
they were made, and we are under no duty to update any of these
forward-looking statements after the date of this press release to
conform our prior statements to actual results or revised
expectations.
Use of Non-GAAP Financial Measures
The Company reports financial results in accordance with
generally accepted accounting principles in the United States
(“GAAP”), however, the Company believes the evaluation of ongoing
operating results may be enhanced by a presentation of Adjusted
EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial
measures.
These non-GAAP financial measures are not intended to replace
financial performance measures determined in accordance with GAAP.
Rather, they are presented as supplemental measures of the
Company's performance that management believes may enhance the
evaluation of the Company's ongoing operating results. These
non-GAAP financial measures are not presented in accordance with
GAAP, and the Company’s computation of these non-GAAP financial
measures may vary from similar measures used by other companies.
These measures have limitations as an analytical tool and should
not be considered in isolation or as a substitute or alternative to
revenue, net income, operating income, cash flows from operating
activities, total indebtedness or any other measures of operating
performance, liquidity or indebtedness derived in accordance with
GAAP.
AirSculpt Technologies, Inc. and
SubsidiariesSelected Consolidated Financial
Data(Dollars in thousands)
|
Three Months EndedDecember 31, |
|
Twelve Months EndedDecember 31, |
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Revenue |
$ |
37,556 |
|
|
$ |
22,843 |
|
|
$ |
133,315 |
|
|
$ |
62,766 |
|
Operating expenses: |
|
|
|
|
|
|
|
Cost of service |
|
13,074 |
|
|
|
7,618 |
|
|
|
44,536 |
|
|
|
23,471 |
|
Selling, general and administrative |
|
34,806 |
|
|
|
7,503 |
|
|
|
65,732 |
|
|
|
23,621 |
|
Loss on debt modification |
|
— |
|
|
|
— |
|
|
|
682 |
|
|
|
— |
|
Depreciation and amortization |
|
1,933 |
|
|
|
1,476 |
|
|
|
6,597 |
|
|
|
5,641 |
|
Total operating expenses |
|
49,813 |
|
|
|
16,597 |
|
|
|
117,547 |
|
|
|
52,733 |
|
(Loss) Income from operations |
|
(12,257 |
) |
|
|
6,246 |
|
|
|
15,768 |
|
|
|
10,033 |
|
Interest expense, net |
|
1,565 |
|
|
|
680 |
|
|
|
4,888 |
|
|
|
2,456 |
|
Pre-tax net (loss) income |
|
(13,822 |
) |
|
|
5,566 |
|
|
|
10,880 |
|
|
|
7,577 |
|
Income tax expense |
|
329 |
|
|
|
— |
|
|
|
329 |
|
|
|
— |
|
Net (loss) income |
$ |
(14,151 |
) |
|
$ |
5,566 |
|
|
$ |
10,551 |
|
|
$ |
7,577 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AirSculpt Technologies, Inc. and
SubsidiariesSelected Financial and Operating
Data(Dollars in thousands, except per case
amounts)
|
December 31,2021 |
|
December 31,2020 |
Balance Sheet Data (at
period end): |
|
|
|
Cash and cash equivalents |
$ |
25,347 |
|
|
$ |
10,379 |
|
Total current assets |
|
29,440 |
|
|
|
11,563 |
|
Total assets |
$ |
200,554 |
|
|
$ |
179,610 |
|
|
|
|
|
Current portion of long-term
debt |
$ |
850 |
|
|
$ |
400 |
|
Deferred revenue and patient
deposits |
|
2,810 |
|
|
|
3,233 |
|
Total current liabilities |
|
16,415 |
|
|
|
9,457 |
|
Long-term debt, net |
|
81,755 |
|
|
|
32,119 |
|
Total liabilities |
$ |
117,026 |
|
|
$ |
55,934 |
|
|
|
|
|
Total member's / stockholders’
equity |
$ |
83,528 |
|
|
$ |
123,676 |
|
|
Three Months EndedDecember
31, |
|
Twelve Months EndedDecember 31, |
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Cash Flow
Data: |
|
|
|
|
|
|
|
Net cash provided by (used
in): |
|
|
|
|
|
|
|
Operating activities |
$ |
(5,706 |
) |
|
$ |
7,200 |
|
|
$ |
26,633 |
|
|
$ |
13,957 |
|
Investing activities |
|
(2,390 |
) |
|
|
(1,146 |
) |
|
|
(7,116 |
) |
|
|
(3,689 |
) |
Financing activities |
|
12,705 |
|
|
|
(2,589 |
) |
|
|
(4,549 |
) |
|
|
(5,017 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
Twelve Months EndedDecember 31, |
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Other
Data: |
|
|
|
|
|
|
|
Number of centers as of the
end of the period |
|
18 |
|
|
|
14 |
|
|
|
18 |
|
|
|
14 |
|
Number of procedure rooms as
of the end of the period |
|
32 |
|
|
|
23 |
|
|
|
32 |
|
|
|
23 |
|
|
|
|
|
|
|
|
|
Cases |
|
2,885 |
|
|
|
2,006 |
|
|
|
11,050 |
|
|
|
5,885 |
|
Revenue per case |
$ |
13,018 |
|
|
$ |
11,387 |
|
|
$ |
12,065 |
|
|
$ |
10,665 |
|
Adjusted EBITDA (1) |
$ |
10,212 |
|
|
$ |
8,120 |
|
|
$ |
46,111 |
|
|
$ |
17,493 |
|
Adjusted EBITDA margin
(2) |
|
27.2 |
% |
|
|
35.5 |
% |
|
|
34.6 |
% |
|
|
27.9 |
% |
(1) A reconciliation of this non-GAAP financial measure appears
below.
(2) Defined as Adjusted EBITDA as a percentage of revenue.
AirSculpt Technologies, Inc. and
SubsidiariesSupplemental
Information(Dollars in thousands, except per case
amounts)
|
Three Months EndedDecember
31, |
|
Twelve Months EndedDecember
31, |
|
|
2021 |
|
|
2020 |
|
|
|
2021 |
|
|
2020 |
|
Same-center
Information (1): |
|
|
|
|
|
|
|
|
|
|
|
Cases |
|
2,388 |
|
|
1,997 |
|
|
|
8,851 |
|
|
5,692 |
|
Case growth |
|
19.6 |
% |
|
N/A |
|
|
|
55.5 |
% |
|
N/A |
|
Revenue per case |
$ |
12,884 |
|
|
$ |
11,394 |
|
|
$ |
11,917 |
|
|
$ |
10,630 |
|
Revenue per case growth |
|
13.1 |
% |
|
N/A |
|
|
|
12.1 |
% |
|
N/A |
|
Number of facilities |
|
13 |
|
|
13 |
|
|
|
11 |
|
|
11 |
|
Number of total procedure
rooms |
|
22 |
|
|
22 |
|
|
|
19 |
|
|
19 |
|
(1) For the three months ended December 31, 2021
and 2020, we define same-center case and revenue growth as the
growth in each of our cases and revenue at facilities that have
been owned and operated since October 1, 2020. We define
same-center facilities and procedure rooms as facilities and
procedure rooms that have been owned or operated since October 1,
2020.
For the twelve months ended
December 31, 2021 and 2020, we define same-center case and
revenue growth as the growth in each of our cases and revenue at
facilities that have been owned and operated since January 1, 2020.
We define same-center facilities and procedure rooms as facilities
and procedure rooms that have been owned or operated since
January 1, 2020.
AirSculpt Technologies, Inc. and
SubsidiariesReconciliation of Non-GAAP Financial
Measures(Dollars in thousands)
We report our financial results in accordance
with GAAP, however, management believes the evaluation of our
ongoing operating results may be enhanced by a presentation of
Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP
financial measures.
We define Adjusted EBITDA as net income (loss)
excluding loss on debt modification, initial public offering
(“IPO”) related costs, sponsor management fee, pre-opening de novo
and relocation costs, restructuring and related severance,
equity-based compensation, depreciation and amortization, interest
expense, net and income tax expense.
We include Adjusted EBITDA because it is an
important measure on which our management assesses and believes
investors should assess our operating performance. We consider
Adjusted EBITDA to be an important measure because it helps
illustrate underlying trends in our business and our historical
operating performance on a more consistent basis. Adjusted EBITDA
has limitations as an analytical tool including: (i) Adjusted
EBITDA does not include results from equity-based compensation and
(ii) Adjusted EBITDA does not reflect interest expense on our
debt or the cash requirements necessary to service interest or
principal payments.
We define Adjusted EBITDA Margin as Adjusted
EBITDA as a percentage of revenue. We included Adjusted EBITDA
Margin because it is an important measure on which our management
assesses and believes investors should assess our operating
performance. We consider Adjusted EBITDA Margin to be an important
measure because it helps illustrate underlying trends in our
business and our historical operating performance on a more
consistent basis.
The following table reconciles Adjusted EBITDA
and Adjusted EBITDA Margin to net income (loss), the most directly
comparable GAAP financial measure:
|
Three Months EndedDecember
31, |
|
Twelve Months EndedDecember
31, |
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Net income (loss) |
$ |
(14,151 |
) |
|
$ |
5,566 |
|
|
$ |
10,551 |
|
|
$ |
7,577 |
|
Plus |
|
|
|
|
|
|
|
Sponsor management fee |
|
969 |
|
|
|
125 |
|
|
|
1,636 |
|
|
|
500 |
|
Equity-based compensation |
|
6,927 |
|
|
|
81 |
|
|
|
7,185 |
|
|
|
325 |
|
Loss on debt modification |
|
— |
|
|
|
— |
|
|
|
682 |
|
|
|
— |
|
IPO related costs |
|
11,837 |
|
|
|
— |
|
|
|
11,837 |
|
|
|
— |
|
Pre-opening de novo and relocation costs |
|
267 |
|
|
|
192 |
|
|
|
1,556 |
|
|
|
879 |
|
Restructuring and related severance costs |
|
536 |
|
|
|
— |
|
|
|
850 |
|
|
|
115 |
|
Depreciation and amortization |
|
1,933 |
|
|
|
1,476 |
|
|
|
6,597 |
|
|
|
5,641 |
|
Interest expense, net |
|
1,565 |
|
|
|
680 |
|
|
|
4,888 |
|
|
|
2,456 |
|
Income tax expense |
|
329 |
|
|
|
— |
|
|
|
329 |
|
|
|
— |
|
Adjusted
EBITDA |
$ |
10,212 |
|
|
$ |
8,120 |
|
|
$ |
46,111 |
|
|
$ |
17,493 |
|
Adjusted EBITDA
Margin |
|
27.2 |
% |
|
|
35.5 |
% |
|
|
34.6 |
% |
|
|
27.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investor ContactDennis DeanChief Financial
Officerinvestors@elitebodysculpture.com
AirSculpt Technologies (NASDAQ:AIRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
AirSculpt Technologies (NASDAQ:AIRS)
Historical Stock Chart
From Apr 2023 to Apr 2024